Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma

Annals of Hematology

Volumn 81, Issue 2, 2002, Pages 96-102

  Hanel M ^a   Kroger N ^b   Sonnenberg, S ^b   Bornhauser M ^a   Kruger W ^b   Kroschinsky, F ^a   Hanel A ^c   Metzner, B ^d   Birkmann, J ^e   Schmid, B ^f   Hoffknecht, M M ^b   Fiedler, F ^c   Ehninger, G ^a   Zander, A R ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c KLINIKUM CHEMNITZ   (Germany)

^d Department of Oncology/Hematology   (Germany)

^e KLINIKUM NÜRNBERG   (Germany)

^f Clinic of Internal Medicine   (Germany)

Author keywords

Busulfan; Cyclophosphamide; Etoposide; High dose chemotherapy; Malignant lymphoma

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DIAZEPAM; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; PHENYTOIN;

ADULT; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROBABILITY; PUBLICATION; RECURRENT CANCER; SCORING SYSTEM; SEIZURE; SURVIVAL TIME; TREATMENT OUTCOME; VEIN OCCLUSION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 0036944074     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-001-0413-8     Document Type: Article

References (44)

1. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, Coiffier B, Colombat P, Cahn JY, Attal M, Fleury J, Milpied N, Nedellec G, Biron P, Tilly H, Jouet JP, Gisselbrecht C (1999) Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. J Clin Oncol 17:222-229
2. Avalos BR, Klein JL, Kapoor N, Tutschka PJ, Klein JP, Copelan EA (1993) Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY Bone Marrow Transplant 12:133-138
3. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562-1568
4. Blume KG, Forman SJ (1992) High-dose etoposide (VP-16)-containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 19 [Suppl 13]:63-66
5. Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW, Kalaycio M, Bechtel TP, Scholl MD, Elder PJ, Ezzone SA, O'Donnell LC, Tighe MB, Risley GL, Young DC, Bolwell BJ (2000) Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 25: 1243-1248
6. Deeg HJ (1994) Delayed complications after bone marrow transplantation. In: Forman SJ, Blume KG, Thomas ED (eds) Bone Marrow Transplantation. Blackwell Scientific Publications, Boston MA, pp 538-544
7. de Magalhaes-Silverman M, Lister J, Rybka WB, Wilson J, Ball E (1997) Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant 19:777-781
8. Gulati S, Yahalom J, Acaba L, Reich L, Motzer R, Crown J, Toia M, Igarashi T, Lemoli R, Hanninen E (1992) Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 10: 936-941
9. Horning SJ, Negrin RS, Chao NJ, Long GD, Hoppe RT, Blume KG (1994) Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 12:2552-2558
10. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 89:801-813
11. Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, Zander AR, Spitzer G (1986) High-dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Int Med 104:163-168
12. Josting A, Katay I, Rueffer U, Winter S, Tesch H, Engert A, Diehl V, Wickramanayake PD (1998) Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 9:289-295
13. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
14. Kewalramani T, Zelenetz AD, Hedrick EE, Donelly GB, Hunte S, Priovolos AC, Jing Q, Lyons NC, Yahalom J, Nimer SD, Moskowitz CH (2000) High-dose chemotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat-analysis. Blood 96:2399-2404
15. Kröger N, Hoffknecht M, Hänel M, Krüger W, Zeller W, Stockschläder M, de Wit M, Weh HJ, Kabisch H, Erttmann R, Zander AR (1998) Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant 21:1171-1175
16. Kröger N, Zabelina. T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Braumann D, Metzner B, Valle F, Erttmann R, Kabisch H, Zander AR (2000) Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant 26:711-716
17. Lancet JE, Rapoport AP, Brasacchio R, Eberly S, Raubertas RF, Linder T, Muhs A, Duerst RE, Abboud CN, Packman CH, DiPersio JF, Constine LS, Rowe JM, Liesveld JL (1998) Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 22:265-271
18. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, bierman PJ, Gajewski JL, Gale RP, Keating A, Klein JP, Miller CB, Phillips GL, Reece DE, Sobocinski KA, Van Besien K, Horowitz MM (1999) Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Registry. J Clin Oncol 17:534-545
19. Lennert K, Feller AC (1992) Histopathology of non-Hodgkin's lymphomas. Springer, Berlin Heidelberg New York Tokyo, pp 13-52
20. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Vaughan Hudson G (1993) Dose identification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051-1054
21. Lukes RJ, Butler JJ (1966) The pathology and nomenclature of Hodgkin's disease. Cancer Res 26:1063-1081
22. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Int Med 118:255-267
23. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 13:588-595
24. Peto R, Peto J (1972) Asymptotically efficient rank invariation test procedures (with discussion). J R Stat Soc A 135:185-206
25. Pfreundschuh MG, Schoppe WD, Fuchs R, Pflüger KH, Löffler M, Diehl V (1987) Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and darcabazine (ABVD): a multi-center trial of the German Hodgkin's Study Group. Cancer Treat Rep 71:1203-1207
26. Pfreundschuh MG, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, Haas R, Kirchner H, Koch P, Loeffler M, Diehl V (1994) Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimes: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 12:580-586
27. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M, Laporte JP, Maraninchi D, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498
28. Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, Spitzer G, Velasquez W, Weisenburger DD, Fernandez-Ranada J (1991) Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 77: 1587-1592
29. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545
30. Prince HM, Imrie K, Crump M, Stewart AK, Girouard C, Colwill R, Brandwein J, Tsang RW, Scott JG, Sutton DMC, Pantalony D, Carstairs K, Sutcliffe SB, Keating A (1996) The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br J Haematol 92:880-889
31. Rapoport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL, Packman CH, Eberly S, Sherman M, Tanner MA, Constine LS, DiPersio JF (1993) One hundred autotransplants for relapsed or refractory Hodgkin's disease: value of pretransplant disease status for predicting outcome. J Clin Oncol 11: 2351-2361
32. Rapoport AP, Lifton R, Constine LS, Duerst RE, Abboud CN, Liesveld JL, Packmann CH, Eberly S, Raubertas RF, Martin BA, Flesher WR, Kouides PA, DiPersio JF, Rowe JM (1997) Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 19:883-890
33. Schmitz N, Sextro M, Pfistner B, Hasenclever D, Tesch H, Carella A, Haenel M, Boissevain F, Zschaber R, Goldstone AH, Diehl V (1999) High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease: final results of a randomized GHSG and EBMT trial (HD-R1). Proc Am Soc Clin Oncol 18:2a
34. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B (1999) International consensus conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 17:423-429
35. Stadtmauer EA, Casslith PA, Gale RP (1989) Etoposide in leukemia, lymphoma and bone marrow transplantation. Leuk Res 13:639-650
36. Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI (1998) Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimes. A Southwest Oncology Group trial. J Clin Oncol 16:48-55
37. Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Volpe AD, Linch DC, Schmitz N, Goldstone AH (1999) High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. J Clin Oncol 17:3101-3109
38. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, Pavlovsky S, Keating A, Yanes B, van Besien K, Armitage JO, Horowitz MM (2001) Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 19:406-413
39. Weaver CH, Petersen FB, Appelbaum FR, Bensinger WI, Press O, Martin P, Sandmaier B, Deeg HJ, Hansen JA, Brunvand M, Rowley S, Benyunes K, Chauncey T, Fefer A, Hackman R, Gooley T, Schiffmann K, Storb R, Sullivan KM, Weiden P, Witherspoon R, Buckner CD (1994) High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem cell support in patients with malignant lymphoma. J Clin Oncol 12:1259-1266
40. Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, Buckner CD (1998) High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 21:383-389
41. Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, Weinstein H, Schwartz G, Ferrara J, Mazanet R, Rimm, IJ, Tepler I, McCarthy P, Mauch P, Ault K, Gayness L, McCauley M, Schnipper LE, Antin J (1993) Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 11:1085-1091
42. Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei III E, Kadin M, Antin J (1997) High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 3:98-106
43. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ (1997) Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89:814-822
44. Zander AR, Berger C, Kröger N, Stockschläder M, Krüger W, Horstmann M, Grimm J, Zeller W, Kabisch H, Erttmann R, Schönrock P, Kuse R, Braumann D, Illiger HJ, Fiedler W, de Wit M, Hossfeld KD, Weh HJ (1997) High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res 3:2671-2675